预测严重高血症的72小时死亡率:在单中心研究中对多变量逻辑回归和机器学习模型进行比较分析
Keishiro Sueda1, Susumu Ookawara1, Kai Saito1
1Comprehensive Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JPN.
Cureus
|April 17, 2025
概括
严重的高酸盐血症显著增加死亡风险. 与传统方法相比,机器学习,特别是LightGBM在预测72小时死亡事故方面表现出更高的准确性.
科学领域:
- 医学预测 医学预测
- 临床数据分析 临床数据分析
- 医疗保健中的机器学习
背景情况:
- 严重的高酸血症 (≥10 mg/dL) 与慢性病和败血症等危急疾病有关.
- 预测这些患者72小时死亡率对于及时干预至关重要.
研究的目的:
- 评估不同预测模型在重度高酸血症患者72小时死亡率的有效性.
- 为了比较多变量物流回归分析 (MLRA) 和机器学习算法 (Prediction OneTM,LightGBM) 的性能.
主要方法:
- 分析了来自530名患者 (2004-2019) 的数据,其中153人死亡.
- 应用MLRA,Prediction OneTM和LightGBM用于死亡预测.
- 在331名患者 (2020-2023) 和104例死亡的单独队列上进行验证.
主要成果:
- 轻GBM实现了最高的曲线下面积 (AUC) 0.948,具有高灵敏度 (0.863) 和特异性 (0.889).
- MLRA显示AUC为0.848并确定了关键预测因素:年龄,低白蛋白,高AST和高/.
- 死亡率在培训中为28.9%,在验证数据中为31.4%.
结论:
- 机器学习模型,特别是LightGBM,在预测严重高酸血症的短期死亡率方面提供了卓越的准确性.
- 准确的预后对于指导紧急干预和改善患者结果至关重要.
- MLRA为重要预后因素提供了宝贵的见解.
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
491
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
491
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97


